AVSF - Neurophos 2025, LLC is a venture capital fund based in Boston, Massachusetts. According to its most recent Form D, filed Dec 29, 2025, it has sold $1,887,000 of interests to 99 investors since its first sale in Dec 2025. The minimum investment it accepts from an outside investor is $10,000. It relies on the Section 3(c)(1) exclusion, which limits it to 100 beneficial owners, typically accredited investors. The offering uses Rule 506(b), which does not permit general solicitation. Based on its first sale date and the amount raised, AltMountain classifies it as an emerging manager. Related persons named in the filing include Michael Collins.
- Total raised
- $1,887,000Cumulative sales reported on Form D
- Investors
- 99
- First sale
- Dec 15, 2025
- Minimum investment
- $10,000
- Who can invest
- Accredited investorsSection 3(c)(1): up to 100 beneficial owners
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Michael Collins
- Latest Form D
- Dec 29, 2025
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about AVSF - Neurophos 2025, LLC
What is the minimum investment for AVSF - Neurophos 2025, LLC?
According to its latest Form D, filed Dec 29, 2025, the minimum investment AVSF - Neurophos 2025, LLC accepts from an outside investor is $10,000.
Who can invest in AVSF - Neurophos 2025, LLC?
AVSF - Neurophos 2025, LLC is generally open only to accredited investors, and it may have no more than 100 beneficial owners because it relies on Section 3(c)(1). It uses Rule 506(b), which does not allow general advertising.
How much has AVSF - Neurophos 2025, LLC raised?
AVSF - Neurophos 2025, LLC reports $1,887,000 sold from 99 investors on its Form D filed Dec 29, 2025. This is cumulative sales since the offering began, not current assets or performance.
Where is AVSF - Neurophos 2025, LLC based?
AVSF - Neurophos 2025, LLC is based in Boston, Massachusetts.
When did AVSF - Neurophos 2025, LLC launch?
AVSF - Neurophos 2025, LLC reports its first sale in Dec 2025, which makes it an emerging manager by AltMountain's definition (first sale in 2021 or later and under $50 million raised).
Size compared with every venture capital fund
Raised more than 71% of the 533 venture capital funds based in Massachusetts, and more than 70% of all 14,876 that report sales.